AstraZeneca's Imfinzi Shows Promise in Bladder Cancer Treatment

Sep 15, 2024, 02:35 PM

AstraZeneca's Imfinzi (durvalumab) has shown promising results in treating muscle-invasive bladder cancer. In the NIAGARA Phase III trial, the perioperative regimen of Imfinzi reduced the risk of recurrence by 32% and the risk of death by 25% compared to neoadjuvant chemotherapy alone. These findings suggest that Imfinzi could potentially extend the lives of bladder cancer patients and open up a new market for the blockbuster medicine. The study's results were highlighted at the ESMO 2024 conference.